Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast


Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

Database Update: Pharmaceutical Drug Import to Russia (September 2017)

Friday, October 13, 2017

During the first three quarters of 2017, Russia imported 372.2 bln RUB worth of ready-made pharmaceuticals (free circulation prices, VAT included), which is in monetary terms 9.5% higher than that of the same period of 2016. Then-bulk imports amounted to 70.1 bln RUB, which is 18% lower than that of the same period of 2016, despite the progress in August. Since January 2017, Russia has imported 442.3 bln RUB worth of pharmaceuticals, with the growth rates amounting to 3.9%, which barely cover the inflationary factor.

However, it does not waver from the season’s trends, with the import of ready-made pharmaceuticals amounting to around 45.2 bln RUB (free circulation prices, VAT included.) The dynamics were even higher than that of August (13.5% against 13.2%). The dynamics of the in-bulk import have once again dropped into the red zone with -39% and 6.7 bln RUB.

In physical terms, the numbers are pretty much the same. Between January and October 20017, Russia imported 1.65 mln worth of ready-made drugs, or around 29.7 bln minimum dosage units (MDU), with a 5.9% rise and a 2.5% fall, respectively. Even though the in-bulk import has risen by 4.3% if calculated in MDU, it does not change the situation drastically, with a 1.8% decrease.

During the first 9 months, GSK had the best dynamics among the 10 largest importers of ready-made pharmaceuticals, with 56%. Among the largest importers of in-bulk products, Novartis had the best dynamics, with 96%.

Read more about pharmaceutical drug import to Russia (August performance) here:

Dynamics of import of pharmaceuticals, including homeopathic and seawater drugs, to Russia, free circulation prices including customs clearance and VAT, RUB (January 2016 – September 2017)